Please use this identifier to cite or link to this item:
https://observatorio.fm.usp.br/handle/OPI/9324
Title: | The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4 |
Authors: | TEIXEIRA, Marcela Crosara; MARQUES, Daniel Fernandes; FERRARI, Anezka Celis; ALVES, Michel Fabiano Silva; ALEX, Alexandra Khichfy; SABBAGA, Jorge; HOFF, Paulo M.; RIECHELMANN, Rachel P. |
Citation: | CLINICAL COLORECTAL CANCER, v.14, n.1, p.52-57, 2015 |
Abstract: | There are no data supporting the effect of systemic chemotherapy on the survival of patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 3 and 4. Among our ECOG PS 3/4 patients with metastatic colorectal cancer (mCRC), patients who received chemotherapy had a survival advantage compared with those given best supportive care (BSC) only. Background: Although chemotherapy is standard for patients with mCRC and ECOG PS of 0/1, the real benefit for patients with ECOG PS > 2 remains uncertain, because they are generally excluded from clinical trials. Our objectives were to compare the survival and safety of ECOG PS 3/4 patients who were administered chemotherapy with those who received BSC only. Patients and Methods: We retrospectively analyzed all consecutive mCRC patients who started first-line chemotherapy at our institution in a 4-year period. A multivariable Cox regression model was used to adjust for prognostic factors and logistic regression, to identify predictive factors of Grade 3/4 toxicity. Results: From June 2008 to June 2012, 240 consecutive patients were included: 100 (41.7%) had an ECOG PS of 0/1, 75 (31.3%) ECOG PS of 2, and 65 (27%) ECOG PS of 3/4. Median survival for patients treated with chemotherapy was 18.4 months for patients with ECOG PS of 0/1, 10.8 months for those with ECOG PS of 2, and 6.8 months for patients with ECOG PS of 3/4. Among those with ECOG PS of 3/4, chemotherapy use led to a nonsignificant survival gain (median, 6.8 vs. 2.3 months for BSC; P = .13). Factors significantly associated with worse survival in an adjusted analysis were right-sided tumors (hazard ratio [HR], 2.97; P = .005) and ECOG PS status (ECOG PS 2 vs. 0/1; HR, 1.67; P = .025, and ECOG PS 3/4 vs. 0/1; HR, 2.67; P < .0001). The rate of Grade >= 3 toxicities during the first cycle did not differ significantly across ECOG groups; likely because 40% of ECOG PS 3/4 patients received upfront dose-reduced therapy. The rates of treatment-related hospitalization were similar across all ECOG groups. All deaths were disease-associated. Conclusion: Our retrospective study suggests that chemotherapy might benefit selected mCRC patients with poor PS. With up-front dose reduction and close monitoring for toxicity, the risk of serious adverse events is minimized. |
Appears in Collections: | Artigos e Materiais de Revistas Científicas - FM/MDR Artigos e Materiais de Revistas Científicas - HC/ICESP Artigos e Materiais de Revistas Científicas - HC/InRad Artigos e Materiais de Revistas Científicas - LIM/24 Artigos e Materiais de Revistas Científicas - ODS/03 |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
art_TEIXEIRA_The_Effects_of_Palliative_Chemotherapy_in_Metastatic_Colorectal_2015.PDF Restricted Access | publishedVersion (English) | 344.08 kB | Adobe PDF | View/Open Request a copy |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.